1. Market Research
  2. > Pharmaceutical Market Trends
  3. > The Payer Landscape in the United States - The Pharmaceutical Industry Faces a Rapidly Changing Marketplace

Managed care began to be developed as early as 1917, with both private and government payers established by the mid-1960s. Medicare and Medicaid are the major government payers, with the health care reform legislation of 2010 providing changes for both. That said, private payers, such as regionals, nationals and blues plans, may take the brunt of the reform policies put in place.

The health care reform legislation in 2010 was the product of extended debate and compromise. The legislation will mean huge changes for the insurance industry if it is enacted. However, the more controversial aspects of the legislation, particularly the Mandate for health insurance, have resulted in numerous challenges.

For pharmaceutical companies, there are potential gains and challenges. Much of the 2010 health care reform legislation is very positive for the industry. If the Supreme Court ruling or the November elections mean that all or much of the legislation is scrapped, then the industry will again have to spend millions of dolloars in lobbying to ensure similar gains in whatever legislation takes its place. Working with payers will also provide the industry with challenges of increased pressure for generics, but may provide opportunities for pharmas to further their relationships with providers.

The report, “The Payer Landscape in the United States - The Pharmaceutical Industry Faces a Rapidly Changing Marketplace”, was written to support pharmaceutical companies with their strategic plans to grow their businesses and prepare for future challenges they’ll soon face within the changing health care playing field.


- Development of payers in the US including history of payers, types of payers
- Details on government payers - Medicare and Medicaid and top private payers
- Health Care Reform and payers – 2010 legislation
- Payer Response to health care reform – changing the business model
- Payers and generics – growth of the generics market
- The Outlook for payers and pharmaceutical companies – new revenue streams

Key Reasons to Purchase

- Understand the changes taking place within the payer landscape and its impact on the pharmaceutical industry
- Look forward to what health care reform will mean to providers relationship with payers
- Assess the potential for biosimilar use by payers given the recent rules outlined by the FDA
- Gain a clearer understanding of providers’ views on the payers that they work with
- Assess the impact that the current health care landscape has on how the pharmaceutical industry works with payers, as well as how it could change based on the upcoming Supreme Court rulings and elections

Table Of Contents

The Payer Landscape in the United States - The Pharmaceutical Industry Faces a Rapidly Changing Marketplace
Executive Summary

Development of Payers in the US
History of payers
Types of payers
Government Payers
Top Private Payers

Health Care Reform and Payers
2010 legislation
Current challenges

Payer Response to Health Care Reform
Changing the business model
New focus on outcomes
Cost-saving measures

Payers and Generics
Growth of the generics market
The outlook for biosimilars
Payer response - a look at Lipitor

The Outlook for Payers and Pharmaceutical Companies
New revenue streams
State exchanges
Supreme Court ruling
Presidential election
Impact on pharmaceutical companies


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.